Monitor for FDA written feedback and the scheduled meeting this quarter — a positive outcome could unlock a new revenue stream via the Helix platform and catalyze partnering deals. The stock may trade on regulatory sentiment until a definitive clearance decision.
Price Chart
Executive Summary
BioCardia announced FDA acceptance of its De Novo pre-submission package for the Helix catheter, a transendocardial delivery device. The FDA will conduct a substantive review and meet with BioCardia this quarter to discuss marketing clearance via the De Novo pathway. This is a regulatory milestone that could enable new partnership opportunities for the company's delivery platform.
Key Facts
- FDA accepted BioCardia's De Novo pre-submission package for the Helix catheter on October 19, 2026.
- FDA substantive review with written feedback and a meeting to discuss approval via the De Novo pathway is expected this quarter.
- The Helix catheter is supported by clinical data from 15 trials involving nearly 500 patients.
- Marketing clearance could expand BioCardia's opportunities to partner with developers of cell, gene, and protein therapeutics requiring targeted cardiac delivery.
- FDA previously agreed there are two pathways for Helix marketing clearance and raised no concerns about safety, performance, or agent compatibility.
Financial Impact
No financial figures disclosed; potential revenue from catheter sales and partnership licensing if clearance is obtained.
Risk Factors
- FDA may request additional data or deny the De Novo request, delaying or preventing commercialization.
- BioCardia's ability to fund operations and pursue partnerships depends on raising additional capital, as noted in forward-looking statements.
- The Helix catheter has not yet received marketing clearance; the outcome of FDA review is uncertain.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032887 |
| Exhibit: ex_1027387.htm | 0001437749-26-032887 |
| Document: 0001437749-26-032887-index-headers.html | 0001437749-26-032887 |
| Document: 0001437749-26-032887-index.html | 0001437749-26-032887 |
| Document: 0001437749-26-032887.txt | 0001437749-26-032887 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9000 (+0.28%) |
Oct 19, 2026 7d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9000 (−0.00%) |
Oct 7, 2026 19d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9000 (−17.43%) |
Oct 1, 2026 25d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Oct 1, 2026 25d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9000 (−18.18%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9000 (−15.09%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9000 (−5.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers